Your browser doesn't support javascript.
loading
Pyrazole diaminopyrimidines as dual inhibitors of KDR and Aurora B kinases.
Curtin, Michael L; Heyman, H Robin; Frey, Robin R; Marcotte, Patrick A; Glaser, Keith B; Jankowski, James R; Magoc, Terrance J; Albert, Daniel H; Olson, Amanda M; Reuter, David R; Bouska, Jennifer J; Montgomery, Debra A; Palma, Joann P; Donawho, Cherrie K; Stewart, Kent D; Tse, Chris; Michaelides, Michael R.
  • Curtin ML; Global Pharmaceutical Research and Development, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, IL 60064-6100, USA. mike.curtin@abbott.com
Bioorg Med Chem Lett ; 22(14): 4750-5, 2012 Jul 15.
Article en En | MEDLINE | ID: mdl-22695126
ABSTRACT
In an effort to identify kinase inhibitors with dual KDR/Aurora B activity and improved aqueous solubility compared to the Abbott dual inhibitor ABT-348, a series of novel pyrazole pyrimidines structurally related to kinase inhibitor AS703569 were prepared. SAR work provided analogs with significant cellular activity, measureable aqueous solubility and moderate antitumor activity in a mouse tumor model after weekly ip dosing. Unfortunately these compounds were pan-kinase inhibitors that suffered from narrow therapeutic indices which prohibited their use as antitumor agents.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Pirazoles / Pirimidinas / Proteínas Serina-Treonina Quinasas / Receptor 2 de Factores de Crecimiento Endotelial Vascular / Inhibidores de Proteínas Quinasas Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Año: 2012 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Pirazoles / Pirimidinas / Proteínas Serina-Treonina Quinasas / Receptor 2 de Factores de Crecimiento Endotelial Vascular / Inhibidores de Proteínas Quinasas Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Año: 2012 Tipo del documento: Article